Literature DB >> 316745

Evaluation of 24-hour infusion of high-dose methotrexate--pharmacokinetics and toxicity.

T S Goh, K Y Wong, B Lampkin, J O'Leary, D Gnarra.   

Abstract

High-dose methotrexate was administered by constant infusion over 24 h to children with various malignancies. Citrovorum factor was given at the completion of methotrexate infusion and continued for 72 h. Serum concentration of 10(-4) M could be sustained for 24 h with doses of methotrexate over 100 mg/kg. This infusion regimen was well tolerated and only mild neutropenia and mouth sores were seen in most patients. Severe toxicity was seen in one patient and was related to prolonged retention of methotrexate in the circulation. Careful monitoring of serum drug level is mandatory in the use of any high-dose methotrexate regimen.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 316745     DOI: 10.1007/bf00262419

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  3 in total

1.  Role of drug concentration, duration of exposure, and endogenous metabolites in determining methotrexate cytotoxicity.

Authors:  H M Pinedo; B A Chabner
Journal:  Cancer Treat Rep       Date:  1977-07

2.  Pharmacokinetic and clinical studies of 24-h infusions of high-dose methotrexate.

Authors:  H J Cohen; N Jaffe
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

3.  Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates.

Authors:  W M Hryniuk; J R Bertino
Journal:  J Clin Invest       Date:  1969-11       Impact factor: 14.808

  3 in total
  10 in total

1.  Evaluation of cytostatic drug concentrations in the kidney, bladder wall, and prostate by means of the diffusion chamber technique in dogs.

Authors:  P Porpaczy; C P Schmidbauer; A Georgopoulos; H Rameis; T A Endler
Journal:  Urol Res       Date:  1983

2.  Pharmacokinetics of high-dose methotrexate in dogs. An experimental model with diffusion chambers.

Authors:  P Porpaczy; C P Schmidbauer; A Georgopoulos; A T Endler
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 3.  Clinical pharmacokinetics of methotrexate in children.

Authors:  Y M Wang; T Fujimoto
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

Review 4.  Dose-dependent pharmacokinetics and cancer chemotherapy.

Authors:  G Powis; M M Ames; J S Kovach
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  High-dose methotrexate: a clinical and pharmacokinetic evaluation. Treatment of advanced squamous cell carcinoma of the head and neck using a prospective mathematical model and pharmacokinetic surveillance.

Authors:  R Favre; S Monjanel; M Alfonsi; J P Pradoura; D Bagarry-Liegey; S Clement; A M Imbert; N Lena; J Colonna d'Istria; J P Cano; Y Carcassonne
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

6.  Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat.

Authors:  E Smeland; R M Bremnes; A Andersen; R Jaeger; T J Eide; N E Huseby; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Effect of combination chemotherapy, duration of methotrexate administration, and patient's age on methotrexate pharmacokinetics.

Authors:  F Lokiec; O Poirier; C Gisselbrecht; M Marty; M Boiron; Y Najean
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Clinical pharmacokinetics of 6-hour infusion of high-dose methotrexate. Preliminary trial of monitoring high infusion doses.

Authors:  M Luyckx; J L Cazin; C Brunet; P Gosselin; M C Demaille
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 9.  Preventing and Managing Toxicities of High-Dose Methotrexate.

Authors:  Scott C Howard; John McCormick; Ching-Hon Pui; Randall K Buddington; R Donald Harvey
Journal:  Oncologist       Date:  2016-08-05

10.  Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein.

Authors:  Kenji Ikemura; Shun-Ichi Hiramatsu; Yuri Shinogi; Yusuke Nakatani; Isao Tawara; Takuya Iwamoto; Naoyuki Katayama; Masahiro Okuda
Journal:  Sci Rep       Date:  2019-12-30       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.